You are here

Alzheimer’s Drug Fails Phase III Study

Immunoglobulin no more effective than placebo (May 7)

A phase III clinical trial of immunoglobulin (IG, Baxter) did not meet its co-primary endpoints of reducing cognitive decline and preserving functional abilities in patients with mild-to-moderate Alzheimer's disease (AD).

Analyses from the randomized, double-blind, placebo-controlled Gammaglobulin Alzheimer's Partnership (GAP) study found that, after 18 months of treatment, patients with mild-to-moderate AD receiving the IG treatment at either the 400 mg/kg or 200 mg/kg dose did not demonstrate a statistically significant difference in the mean rate of cognitive decline compared with placebo (7.4 in the 400 mg/kg group, 8.9 in the 200 mg/kg group, and 8.4 in the placebo group). The results also did not indicate a statistically significant mean change in functional ability compared with placebo (–11.4 in the 400 mg/kg group, –12.4 in the 200 mg/kg group, and –11.4 in the placebo group).

While the study was not powered to show statistical significance among the subgroups in a pre-specified subgroup analysis, the 400 mg/kg treatment arm showed a positive, numerical difference in the change from baseline in cognition versus placebo, as measured by the Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS-Cog) and the Modified Mini-Mental State (3MS) examination among both patients with moderate AD and carriers of the ApoE4 genetic marker. These differences ranged between 16% and 29%.

Based on these results, the drug’s developer (Baxter) will discontinue current studies of IG in mild-to-moderate AD.

The GAP trial enrolled 390 patients with mild-to-moderate AD in the U.S. and Canada. The patients were randomly assigned to receive either IG treatment (400 mg/kg or 200 mg/kg) or placebo every 2 weeks for 18 months. All of the patients were required to maintain their treatment regimen of approved medications for AD symptom management.

Source: Baxter; May 7, 2013.

Recent Headlines

U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs